Similarly, a four-gene IFN-γ signature (IFNG, CD274, LAG3, and CXCL9) has been suggested as identifying pattern for urothelial and NSCLC patients who can benefit from the anti-PD-L1 antibody durvalumab [104, 105]. Here, CD274 is linked to non-small cell lung carcinoma.